Impact of a Dedicated Inpatient Radiation Oncology Consult Service on Goal-Concordant Care
The IROC service was associated with reduced hospital LOS, increased use of hypofractionated approaches, and decreased treatments for patients discharged to hospice. Our findings demonstrate the value of a dedicated program addressing radiation delivery to hospitalized patients to improve goal-concordant treatments. The financial impact of reducing low-value care is an important subject for future investigations.
Authors
- Puneeth Iyengar (ORCID: https://orcid.org/0000-0003-3740-7915)
- Victoria Brennan (ORCID: https://orcid.org/0000-0003-4931-1515)
- Amy Xu (ORCID: https://orcid.org/0000-0001-9650-9458)
- Divya Yerramilli (ORCID: https://orcid.org/0000-0003-3565-5018)
- Daniel Richard Gomez (ORCID: https://orcid.org/0009-0003-8617-3868)
- Simon N. Powell (ORCID: https://orcid.org/0000-0002-8183-4765)
- Jonathan T. Yang (ORCID: https://orcid.org/0000-0001-9375-7384)
- Lillian A. Boe (ORCID: https://orcid.org/0000-0001-6279-9987)
- Morgan E. Freret (ORCID: https://orcid.org/0000-0001-5189-716X)
- C. Jillian Tsai (ORCID: https://orcid.org/0009-0004-8051-0787)
- Oren Cahlon
- Sean McBride (ORCID: https://orcid.org/0000-0002-3055-793X)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- University of Miami (US)
- Princess Margaret Cancer Centre (CA)
- NYU Langone Health (US)
- Cancer Research And Biostatistics (US)
- Sylvester Comprehensive Cancer Center (US)
Publication Details
- Journal
- Advances in Radiation Oncology
- Published
- 2025-10-25
- DOI
- https://doi.org/10.1016/j.adro.2025.101939
- Primary Topic
- Management of metastatic bone disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- AstraZeneca
- Varian Medical Systems
- Gerstner Family Foundation
- Novocure
- Incyte
- National Institutes of Health
- National Cancer Institute
- Janssen Pharmaceuticals